INTRODUCTION
There are clear guidelines for the use of anti-D immunoglobulin both during pregnancy and post-delivery (Lee et al., 1991) . Perinatal losses due to Rh haemolytic disease have been reduced dramatically since anti-D was introduced (Hussey & Clarke 1991; Selinger, 1991) . However, a small number of pregnant rhesus negative women (approximately 1%) become immunized each year in spite of the availability of prophylaxis.
Use of anti-D in A&E 307 PATIENTS AND METHODS
A retrospective review was made of patients presenting to the A&E department in February 1992 with vaginal bleeding in pregnancy who were discharged home. Those patients who were admitted to hospital or were seen solely by a gynaecologist were excluded from the study.
In each case the gestation of pregnancy, clinical diagnosis and maternal blood group details were noted.
RESULTS
A total of 39 patients were seen by the A&E medical staff. Of these, 29 were discharged home, either directly from the department or following review by the gynaecology senior house officer. The blood group was checked in only eight of these 29 patients.
It was possible to determine the blood group of a further 12 patients through the blood transfusion laboratory (from samples taken on previous or subsequent occasions).
A total of five patients were found to be rhesus negative. One of these was known to be rhesus negative at the time of discharge; one had had a sample taken but the result was not retrieved. The remaining three were discharged without the blood group being determined. None of these five patients received anti-D when they were discharged (Table 1) . One patient was admitted subsequently with increased bleeding and was given anti-D at that time.
DISCUSSION
Prevention ot rhesus haemolytic disease is safe and simple; treatment includes invasive procedures such as intrauterine transfusion. Awareness of the need for anti-D administration following potential sensitizing events is the key to prevention (Table 2) .
Women who have bleeding in pregnancy commonly present to the A&E Determining maternal rhesus status should form part of their assessment, and anti-D given as appropriate. The blood group will be recorded on the patient's ante natal card if she has been booked into ante natal clinic; otherwise a sample should be taken.
The recommendations for the use of anti-D in miscarriage are given in Table 3 . It can be seen that anti-D should be given to rhesus negative women with threatened miscarriage of any gestation, or a complete miscarriage of greater than 12 weeks gestation. Rhesus negative women who undergo an evacuation of retained products of conception (ERPC) for incomplete or missed abortion will be given anti-D on the ward.
For pregnancies of less than 20 weeks gestation 250 i.u. of anti-D are given intramuscularly within 96 h of the onset of bleeding. This should be repeated at 6-weekly intervals if bleeding continues intermittently. Anti-D is not required if the patient already has immune anti-D. The recommendations for other events, e.g. antepartum haemorrhage, are not given as these patients would be admitted.
It is recommended that the patient's blood group is determined before discharge so that anti-D can be given when appropriate. However, if this is difficult (e.g. during the night) and the patient is returning well within the 96-h limit for an ultrasound scan, then the result can be retrieved on the second attendance.
In this small study, 21/29 (72%) patients had no rhesus status recorded; this was marginally better than a similar Canadian study in which 38/44 (86%) blood groups were unrecorded (Grant & Hyslop 1991) . It is a cause for concern that none of the patients were given anti-D.
In order to remedy this situation, we have introduced a practical reminder for the medical staff. A stamp is kept with the pregnancy testing kits and this is used group.bmj.com
